Ad

NUVB

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

2

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 4.6

Low: 2.5

High: 6

Total Analysts: 7

Company Profile

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer. The Company is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal (BET) inhibitor, NUV-569 a Wee1 inhibitor, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform. Its lead product candidate, NUV-422, is a selective small molecule inhibitor of CDK 2, 4 and 6. Its second product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. It is developing, including NUV-569, NUV-569 is a differentiated oral small molecule selective inhibitor of Wee1 kinase, an important regulator of deoxyribonucleic acid (DNA) damage repair. Its subsidiaries include Nuvation Holdings, LLC and RePharmation Ltd.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses